June 04, 2026 a 11:31 am
MRK: Dividend Analysis - Merck & Co., Inc.
Merck & Co., Inc., a leader in the pharmaceutical sector, offers a stable dividend profile with its commitment to shareholders as validated by its 57-year dividend history. With a dividend yield of 2.93%, it presents an average income opportunity for investors while maintaining sufficient earnings growth potential. The firm’s dividend sustainability is reinforced by a reasonable payout ratio and continuous cash flow generation.
📊 Overview
Merck & Co., Inc. is positioned in the pharmaceutical sector, guided by a reliable dividend yield and robust dividend history.
| Metric | Details |
|---|---|
| Sector | Pharmaceuticals |
| Dividend yield | 2.93 % |
| Current dividend per share | 3.27 USD |
| Dividend history | 57 years |
| Last cut or suspension | None |
🗣️ Dividend History
Merck's strong dividend history demonstrates its commitment to maintaining and increasing shareholder returns, which is critical for income-focused investors.
| Year | Dividend per Share (USD) |
|---|---|
| 2026 | 1.70 |
| 2025 | 3.28 |
| 2024 | 3.12 |
| 2023 | 2.96 |
| 2022 | 2.80 |
📈 Dividend Growth
Over recent years, Merck has shown a respectable growth in dividends, indicative of its financial health and strategic management. The growth reflects the firm's potential to enhance shareholder value continuously.
| Time | Growth |
|---|---|
| 3 years | 5.42 % |
| 5 years | 6.75 % |
The average dividend growth is 6.75% over 5 years. This shows moderate but steady dividend growth.
📉 Payout Ratio
Understanding the payout ratio helps evaluate the safety of the dividend payment, ensuring that it is supported by both earnings and cash flow.
| Key figure | Ratio |
|---|---|
| EPS-based | 90.41 % |
| Free cash flow-based | 57.18 % |
With an EPS-based payout of 90.41%, Merck's dividend payout borders on the higher side, suggesting limited room for aggressive future increases without substantial earnings improvements. In contrast, the FCF payout ratio of 57.18% is more sustainable, indicating adequate cash flow coverage.
✅ Cashflow & Capital Efficiency
Merck's cash flow management and capital investment efficiency are critical for maintaining dividend stability and enabling future growth.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Free Cash Flow Yield | 4.69% | 7.18% | 3.21% |
| Earnings Yield | 6.93% | 6.79% | 0.13% |
| CAPEX to Operating Cash Flow | 24.96% | 15.70% | 29.70% |
| Stock-based Compensation to Revenue | 0% | 1.19% | 1.07% |
| Free Cash Flow / Operating Cash Flow Ratio | 75.04% | 84.29% | 70.30% |
The cash flow consistently covers capital expenditures and dividend commitments, supporting stable dividend payments and the potential for reinvestment in growth initiatives.
⚠️ Balance Sheet & Leverage Analysis
The balance sheet and leverage metrics underscore Merck's financial solidity and its capacity to sustain obligations while funding growth.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Debt-to-Equity | 0.96 | 0.83 | 0.97 |
| Debt-to-Assets | 0.37 | 0.33 | 0.34 |
| Debt-to-Capital | 0.49 | 0.45 | 0.49 |
| Net Debt to EBITDA | 1.23 | 0.97 | 4.26 |
| Current Ratio | 1.54 | 1.36 | 1.25 |
| Quick Ratio | 1.30 | 1.15 | 1.00 |
| Financial Leverage | 2.60 | 2.53 | 2.84 |
The analysis indicates solid financial health with moderate leverage, suggesting the company can prudently manage its debt obligations.
✅ Fundamental Strength & Profitability
Merck’s profitability margins and returns highlight its fundamental operational efficiency and ability to generate returns on equity and assets.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Return on Equity | 34.70% | 36.96% | 0.97% |
| Return on Assets | 13.34% | 14.62% | 0.34% |
| Margins: Net | 28.11% | 26.68% | 0.61% |
| EBIT | 36.17% | 33.05% | 5.05% |
| EBITDA | 45.17% | 40.06% | 11.49% |
| Gross | 71.98% | 76.32% | 73.17% |
| Research & Development to Revenue | 19.27% | 27.95% | 50.79% |
Merck's strong profitability metrics reaffirm its ability to reinvest capital effectively and capitalize on its R&D investments, promising long-term growth.
📉 Price Development
🗣️ Dividend Scoring System
| Criterion | Details | Score |
|---|---|---|
| Dividend yield | 2.93% | |
| Dividend Stability | 57 years | |
| Dividend growth | 6.75% over 5 years | |
| Payout ratio | EPS: 90.41% FCF: 57.18% | |
| Financial stability | Solid leverage | |
| Dividend continuity | Consistent | |
| Cashflow Coverage | Adequate | |
| Balance Sheet Quality | Good |
Total Score: 32/40
✅ Rating
Merck & Co., Inc. maintains a solid and reliable dividend profile, well-supported by its stable cash flow and robust financial health. Its consistent dividend growth and strong historical track suggest a resilient investment for income-focused portfolios. Investors may consider Merck as a viable option for steady long-term growth and dependable income.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years